Recombinant porcine FcRn/FCGRT & B2M Heterodimer Protein, SPR verified, 50 µg

Background
FCGRT & B2M heterodimer protein (FcRn complex) consist of two subunits: p51 (equivalent to FCGRT), and p14 (equivalent to beta-2-microglobulin), and forms an MHC class I-like heterodimer. Fc fragment of IgG, receptor, transporter, alpha (FCGRT) binds to the Fc region of monomeric immunoglobulins gamma and mediates the uptake of IgG from milk. FCGRT possible role in transfer of immunoglobulin G from mother to fetus. Beta-2-microglobulin (B2M) is a component of the class I major histocompatibility complex (MHC) and involved in the presentation of peptide antigens to the immune system.

Source
Recombinant Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag (SPR verified) (FCM-P5280) is expressed from human 293 cells (HEK293). It contains AA Asp 16 - Ser 289 (FCGRT) & Val 21 - His 118 (B2M) (Accession # Q6XAV9-1 (FCGRT) & Q07717-1 (B2M)).
Predicted N-terminus: Asp 16 (FCGRT) & Val 21 (B2M)mined in a SPR assay (Biacore T200) (QC tested).

Molecular Characterization
Porcine FCGRT&B2M Heterodimer Protein, His Tag&Strep II Tag, produced by co-expression of FCGRT and B2M, has a calculated MW of 32.3 kDa (FCGRT) and 12.8 kDa (B2M). Subunit FCGRT is fused with a polyhistidine tag at the C-terminus and subunit Beta-2 microglobulin (B2M) is fused with a Strep II tag at the C-terminus. The reducing (R) protein migrates as 36 kDa (FCGRT) and 15 kDa (B2M) respectively.

Endotoxin
Less than 1.0 EU per μg of the Rat FcRn / FCGRT & B2M by the LAL method.

Purity
>95% as determined by SDS-PAGE.

Formulation
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally Mannitol or Trehalose are added as protectants before lyophilization.
Contact us for customized product form or formulation.

Reconstitution
See Certificate of Analysis for details of reconstitution instruction and specific concentration.

Storage
Avoid repeated freeze-thaw cycles.
No activity loss was observed after storage at:
In lyophilized state for 1 year (4°C-8°C); After reconstitution under sterile conditions for 1 month (4°C-8°C) or 3 months (-20°C to -70°C).

Bioactivity
Please refer to product data sheet.

References

(1) Goebl NA., et al., 2008, Mol. Biol. Cell 19 (12): 5490–505.
(2) Lee TY., et al., 2008, Clin. Cancer Res. 14 (5): 1487–93.
(3) Güssow D., et al., 1987, J. Immunol. 139 (9): 3132–8.
(4) Gorevic P.D., et al., 1986, Proc. Natl. Acad. Sci. U.S.A. 83:7908-7912.